PRESS RELEASE | Basel, December 18, 2018

Versameb AG, a Swiss biopharmaceutical company, announced today the successful closing of a Seed B financing round, bringing the total capital raised to date to CHF 5.3 millions. Versameb AG is developing a technology platform for transformative therapies, focusing on regenerative medicine through the local application of messenger ribonucleic acid (mRNA).